Eli Lilly (LLY) Receivables - Other (2012 - 2026)

Eli Lilly (LLY) has reported Receivables - Other for 15 consecutive years, with $2.7 billion the latest figure, recorded in Q1 2026.

• Receivables - Other for Q1 2026 came in at $2.7 billion, up 39.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 39.73% YoY), and the FY2025 annual result was $2.4 billion, up 5.51% from the prior year.
• Receivables - Other was $2.7 billion for Q1 2026 at Eli Lilly, up from $2.4 billion in the prior quarter.
• Over five years, Receivables - Other peaked at $3.3 billion in Q3 2025 and troughed at $1.3 billion in Q2 2022.
• Average Receivables - Other over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2024.
• Year-over-year, Receivables - Other declined 20.02% in 2024 and soared 90.67% in 2025.
• Over 5 years, Receivables - Other stood at $1.7 billion in 2022, then soared by 35.05% to $2.2 billion in 2023, then rose by 1.08% to $2.3 billion in 2024, then grew by 5.51% to $2.4 billion in 2025, then gained by 14.74% to $2.7 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $2.7 billion in Q1 2026, $2.4 billion in Q4 2025, and $3.3 billion in Q3 2025.